Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration

Table 4 Estimates for cost and utility model variables

	Health states (Visual acuity measured in letters read)
	90	75	60	45	≤ 30
Annual costs*
Medical care
AMD -related^†	$645	$645	$645	$645	$645
Non eye-related^‡	-	-	$2,288	$2,288	$3,445
Total medical care	$645	$645	$2,933	$2,933	$4,090
Caregivers^§	-	$795	$3,625	$14,185	$47,086
Total	$645	$1,440	$6,558	$17,118	$51,176
Utility values^¶
	0.89	0.89	0.81	0.57	0.52

* 2004 U.S. dollars
† AMD = age-related macular degeneration. Excluding costs of ranibizumab acquisition and administration. Source: Halpern et al.[15]
‡ Source: Javitt et al.[16]
§Source: Schmier et al.[17]
¶Source: Brown et al.[18]

ISSN: 1478-7547